Acute exacerbation of chronic obstructive pulmonary disease in primary care setting in Spain: the EPOCAP study

Therapeutic Advances in Respiratory Disease
C MurioJuan Ruiz-Manzano

Abstract

The present study was designed to describe the clinical profile of acute exacerbations of chronic obstructive pulmonary disease (COPD) and the treatment prescribed by primary care physicians (PCPs) in Spain. An observational, multicenter and cross-sectional study was performed in patients diagnosed with acute exacerbation of COPD and treated by PCPs. Patients diagnosed with asthma, cystic fibrosis, significant bronchiectasis or pneumonia were not included in the study. A total of 329 general physicians recruited 1088 evaluable patients across the country. Mean age was 66.5+/-10.2 years; male : female ratio was 3 : 1. Spirometry was performed in 28.3% of the patients. The number of acute exacerbations in the last year was 3.3+/-2.5; 88.7% had increased expectoration, 87.5% increased dyspnea, 64.4% increased sputum purulence, and 43.5% fever. A total of 6.1% (n = 59) of patients were hospitalized due to exacerbation. The most frequently prescribed medications were antibiotics (84.5%, n = 919), mucolytic agents (72.5%, n = 789), inhaled corticosteroids (ICs) (71.3%, n = 776), and short-acting beta-adrenergic drugs (67.8%, n = 738). Oral corticosteroids were prescribed to 436 patients (40.1%). The clinical profile of acute exacerba...Continue Reading

References

Feb 1, 1987·Annals of Internal Medicine·N R AnthonisenN A Nelson
May 20, 1999·Archivos de bronconeumología·M MiravitllesJ L Segú
May 12, 2000·Archives of Physical Medicine and Rehabilitation·A BelloneR Adone
Apr 3, 2001·Annals of Internal Medicine·V SnowUNKNOWN Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American Col
Apr 11, 2001·Chest·V SnowUNKNOWN Joint Expert Panel on COPD of the American College of Chest Physicians and the American College of Physicians-Amercian Socie
Jun 20, 2001·Archivos de bronconeumología·J A BarberàUNKNOWN Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
May 15, 2002·Chest·Marc MiravitllesUNKNOWN DAFNE Study Group. Decisiones sobre Antibioticoterapia y Farmacoeconomía en la EPOC
Feb 26, 2003·Revue des maladies respiratoires·A CuvelierF Chabot
Mar 4, 2003·Thorax·W MacNee, P M A Calverley
Jun 11, 2003·The European Respiratory Journal. Supplement·S Burge, J A Wedzicha
Apr 13, 2005·Respiration; International Review of Thoracic Diseases·Karl O Fagerström
May 17, 2006·Primary Care Respiratory Journal : Journal of the General Practice Airways Group·C P Onno van Schayck, Janneke Kaper
Jul 13, 2006·Respiratory Medicine·José L Viejo-BañuelosArturo Fueyo-Rodríguez
Dec 21, 2006·Archivos de bronconeumología·Karlos NaberanMarc Miravitlles
Apr 24, 2007·Respiratory Medicine·Marc MiravitllesAntonio Martin
May 18, 2007·American Journal of Respiratory and Critical Care Medicine·Klaus F RabeUNKNOWN Global Initiative for Chronic Obstructive Lung Disease
Nov 3, 2009·Therapeutic Advances in Respiratory Disease·Marc MiravitllesKathrin Stauch

❮ Previous
Next ❯

Citations

Nov 12, 2013·Drugs·Amany F ElbehairyDenis E O'Donnell
Mar 7, 2012·Respirology : Official Journal of the Asian Pacific Society of Respirology·Carl LlorMarc Miravitlles
May 10, 2018·Internal Medicine Journal·John TavernerNatasha Smallwood

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Chest
M MiravitllesDAFNE Study Group. Decisiones sobre Antibioticoterapia y Farmacoeconomía en la EPOC
© 2021 Meta ULC. All rights reserved